CLX Investment Company Announces Standing Monthly Manufacturing Order to Satisfy Growing Distribution Demand for Zonda Products.

TEMECULA, Calif. -- CLX Investment Company (OTCBB:CLXN) today reported that, due to the growing distribution of its diagnostic test for Chlamydia in European markets, portfolio company Zonda, Inc. has placed a standing order with its manufacturer for monthly production of the HandiLab-C test.

The standing order provides a number of advantages to Zonda, including lowering the per unit production price of the Chlamydia test, which is marketed under the HandiLab-C name, and guaranteeing the timely availability of the finished product. This gives Zonda additional lead-time to meet shipping and delivery deadlines -- a critical element as the company expands the distribution of its products from selected European countries to markets around the world.

Medical Packaging Corporation, the manufacturer of the HandiLab-C test, is a leader in the manufacture of custom-collection and testing devices and has over 30 years of experience helping customers discover the highest quality and most cost-effective packaging solutions for its products. MPC delivers turnkey manufacturing and assembly solutions, as well as assisting with design packaging, sourcing of materials, logistics and building to order.

"This is an important step in the development of Zonda as a growing force in the diagnostic testing industry," stated Tammy D. Dunn, chief executive officer of CLX Investment Company. "Obviously, a lower per unit cost increases Zonda's profitability on each shipment, but almost as important a factor is that a standing order with Medical Packaging Corporation immediately raises the priority of Zonda's orders and ensures that the company can successfully deliver its HandiLab-C devices to a growing number of distributors.

"Not only has distribution grown significantly in the past several months, but we expect that a number of new European countries will soon begin carrying HandiLab-C, and securing the increased supply of this product is necessary for the continued expansion of Zonda worldwide distribution program," added Ms. Dunn

About Zonda, Inc.

Zonda Inc., in which CLX holds a 31% equity interest, is expanding the distribution of its product lines into broader markets around the world. The company's product line includes innovative, rapid, self-contained diagnostic device for the detection of Chlamydia, gonorrhea, yeast and Strep A. The Chlamydia test is currently being distributed in an expanding number of European countries and carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Strep A tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to other testing methods), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About the Company

CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets. Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.